Trifluoroacetic acid → HCID 86727668、化合物
反応式
C(O)(C(F)(F)F)=O.[NH2:8][C:9]1[N:10]=[CH:11][C:12]([C:24]2[N:28]([CH2:29][CH3:30])[N:27]=[C:26]([CH:31]3[CH2:36][CH2:35][N:34](C(OC(C)(C)C)=O)[CH2:33][CH2:32]3)[N:25]=2)=[N:13][C:14]=1[C:15]1[O:16][C:17]([C:20]([CH3:23])([CH3:22])[CH3:21])=[N:18][N:19]=1>C(Cl)Cl>[C:20]([C:17]1[O:16][C:15]([C:14]2[C:9]([NH2:8])=[N:10][CH:11]=[C:12]([C:24]3[N:28]([CH2:29][CH3:30])[N:27]=[C:26]([CH:31]4[CH2:36][CH2:35][NH:34][CH2:33][CH2:32]4)[N:25]=3)[N:13]=2)=[N:19][N:18]=1)([CH3:21])([CH3:22])[CH3:23]参加物
実験手順
TFA (400 mL) was added portionwise to a solution of tert-butyl 4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1H-1,2,4-triazol-3-yl)piperidine-1-carboxylate (126 g, 253.22 mmol) in DCM (400 mL). The mixture was stirred for 16 hours at room temperature. The mixture was concentrated under reduced pressure, dissolved in DCM (1 L) and added slowly to a vigorously stirred solution of concentrated aqueous ammonia (500 mL) in water at 0° C. The organic solution was separated from the aqueous and concentrated under reduced pressure* to afford 3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-5-(1-ethyl-3-(piperidin-4-yl)-1H-1,2,4-triazol-5-yl)pyrazin-2-amine (101 g, 100%) as a yellow solid: 1H NMR Spectrum: (DMSO-d6) 1.4-1.52 (12H, m), 1.57-1.73 (2H, m), 1.83-1.93 (2H, m), 2.57-2.7 (2H, m), 2.71-2.84 (1H, m), 2.96-3.09 (2H, m), 4.58 (2H, q), 8.06 (2H, s), 8.84 (1H, s); Mass Spectrum [M+H]+=398.
後処理
- concentrationThe mixture was concentrated under reduced pressure
- dissolutiondissolved in DCM (1 L)
- additionadded slowly to a vigorously stirred solution of concentrated aqueous ammonia (500 mL) in water at 0° C
- customThe organic solution was separated from the aqueous and
- concentrationconcentrated under reduced pressure*
出典と根拠
- ORDレコード
- ord-2c01631d67da49b7946489b481a1b852
- 出典データセット
- uspto-grants-2015_10
- 特許番号
- US09156831B2
反応ノート
読み込み中…